^
Association details:
| Biomarker: | PBRM1 mutation |
|---|---|
| Cancer: | Bladder Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response
Published date:
08/20/2020
Excerpt:
To assess the impact of PBAF complex mutations in non-RCC cohorts treated with ICB profiled with MSK-IMPACT, we restricted our analysis to 11 tumor types with at least 50 patients and at least 5 patients with PBRM1 or ARID2 mutations (n = 2936)...When univariately examining LOF mutations in PBRM1 and ARID2 as well as LOF in PBRM1 alone...A significant correlation with adverse OS was also seen in bladder cancer (n = 245; HR 11.85, p < 0.001); however, only three PBRM1 mutants comprised this group.
DOI:
10.1038/s41467-020-17965-0
